Paper39242587
Progress on the research and development of plague vaccines with a call to action.
Williamson ED and 5 others. NPJ Vaccines, 2024. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Progress on the research and development of plague vaccines with a call to action. Papers, record 39242587. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39242587
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AI153524 | NIAID NIH HHS | United States | R01AI153524 | PubMed | NIH RePORTER |
| T32 AI060549 | NIAID NIH HHS | United States | T32AI060549 | PubMed | NIH RePORTER |
| T32 AI141349 | NIAID NIH HHS | United States | T32AI141349 | PubMed and NIH | NIH RePORTER |
| T32AI179595 | NIH | NIH RePORTER |
References129
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38605961 | Co-formulation of the rF1V plague vaccine with depot-formulated cytokines enhances immunogenicity and efficacy to elicit protective responses against aerosol challenge in mice. | Front Immunol | 2024 | https://conductscience.org/library/papers/38605961 | PubMed |
| 2 | 9682370 | Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. | Vaccine | 1998 | https://conductscience.org/library/papers/9682370 | PubMed |
| 3 | 31964555 | Subcutaneous vaccination with a live attenuated Yersinia pseudotuberculosis plague vaccine. | Vaccine | 2020 | https://conductscience.org/library/papers/31964555 | PubMed |
| 4 | 8418045 | Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. | Infect Immun | 1993 | https://conductscience.org/library/papers/8418045 | PubMed |
| 5 | 17005799 | Resistance of Yersinia pestis to antimicrobial agents. | Antimicrob Agents Chemother | 2006 | https://conductscience.org/library/papers/17005799 | PubMed |
| 6 | 35715352 | Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. | Vaccine | 2022 | https://conductscience.org/library/papers/35715352 | PubMed |
| 7 | 37954941 | The efficacy, safety, and immunogenicity of plague vaccines: A systematic literature review. | Curr Res Immunol | 2023 | https://conductscience.org/library/papers/37954941 | PubMed |
| 8 | 14651623 | Lack of O-antigen is essential for plasminogen activation by Yersinia pestis and Salmonella enterica. | Mol Microbiol | 2004 | https://conductscience.org/library/papers/14651623 | PubMed |
| 9 | 20180652 | Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. | Hum Gene Ther | 2010 | https://conductscience.org/library/papers/20180652 | PubMed |
| 10 | 11313139 | The failure of different strains of Yersinia pestis to produce lipopolysaccharide O-antigen under different growth conditions is due to mutations in the O-antigen gene cluster. | FEMS Microbiol Lett | 2001 | https://conductscience.org/library/papers/11313139 | PubMed |
| 11 | 37289480 | Functional assays to screen and select monoclonal antibodies that target Yersinia pestis. | Hum Vaccin Immunother | 2023 | https://conductscience.org/library/papers/37289480 | PubMed |
| 12 | 13808585 | The role of multiplication of Pasteurella pestis in mononuclear phagocytes in the pathogenesis of flea-borne plague. | J Immunol | 1959 | https://conductscience.org/library/papers/13808585 | PubMed |
| 13 | 38029221 | A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague. | Front Microbiol | 2023 | https://conductscience.org/library/papers/38029221 | PubMed |
| 14 | 19490834 | Enhanced vaccine antigen delivery by Salmonella using antibiotic-free operator-repressor titration-based plasmid stabilisation compared to chromosomal integration. | Microb Pathog | 2009 | https://conductscience.org/library/papers/19490834 | PubMed |
| 15 | 19200825 | A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. | Vaccine | 2009 | https://conductscience.org/library/papers/19200825 | PubMed |
| 16 | 37029123 | Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37029123 | PubMed |
| 17 | 21763383 | Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines. | Vaccine | 2011 | https://conductscience.org/library/papers/21763383 | PubMed |
| 18 | 30985006 | Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization. | Clin Exp Immunol | 2019 | https://conductscience.org/library/papers/30985006 | PubMed |
| 19 | 31199832 | Human response to live plague vaccine EV, Almaty region, Kazakhstan, 2014-2015. | PLoS One | 2019 | https://conductscience.org/library/papers/31199832 | PubMed |
| 20 | 30504873 | Comparing phenotypic variation between inbred and outbred mice. | Nat Methods | 2018 | https://conductscience.org/library/papers/30504873 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42892921 | Combination of live-attenuated and adenovirus-based vaccines provides immediate and durable protection against Yersinia pestis in mice. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42892921 | PubMed |
| 42485432 | Live attenuated vaccines alone or in combination with an adenovirus-based vaccine protect mice lacking IFN-γ against pneumonic plague. | Sci Transl Med | 2026 | https://conductscience.org/library/papers/42485432 | PubMed |
| 42104293 | The impact of the COVID-19 pandemic on healthy volunteer motivations: a mixed-methods study of participants in plague vaccine trials in the UK and Uganda. | BMC Public Health | 2026 | https://conductscience.org/library/papers/42104293 | PubMed |
| 41594581 | Virulence Reduction in Yersinia pestis by Combining Delayed Attenuation with Plasmid Curing. | Biomolecules | 2025 | https://conductscience.org/library/papers/41594581 | PubMed |
| 41530150 | Intranasal unadjuvanted LcrV boosts parental Yersinia OMV primed lung immunity against pneumonic plague in mice. | Nat Commun | 2026 | https://conductscience.org/library/papers/41530150 | PubMed |
| 41153833 | Plagued by the Past, Pressed by the Present: A One Health Perspective on Yersinia pestis. | Biomedicines | 2025 | https://conductscience.org/library/papers/41153833 | PubMed |
| 41071737 | Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network. | Clin Infect Dis | 2025 | https://conductscience.org/library/papers/41071737 | PubMed |
| 40972648 | Lipid A mimetic BECC438 potentiates durable and balanced antibody responses in an ovalbumin murine model of vaccination. | Immunohorizons | 2025 | https://conductscience.org/library/papers/40972648 | PubMed |
| 40529698 | Biological threat preparedness through vaccine development and stockpiling: challenges and strategic implications. | Front Public Health | 2025 | https://conductscience.org/library/papers/40529698 | PubMed |
| 40417828 | rLVS ΔcapB/Yp F1-V single vector platform vaccine expressing Yersinia pestis F1 and LcrV antigens provides complete protection against lethal respiratory challenge with virulent plague bacilli. | Hum Vaccin Immunother | 2025 | https://conductscience.org/library/papers/40417828 | PubMed |
| 40279638 | Novel Bivalent mRNA-LNP Vaccine for Highly Effective Protection against Pneumonic Plague. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40279638 | PubMed |
| 40022523 | Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical Trials. | Med Sci Monit | 2025 | https://conductscience.org/library/papers/40022523 | PubMed |
| 39852845 | Live Plague Vaccine Development: Past, Present, and Future. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/39852845 | PubMed |
| 39772023 | The Protective Effect of IL-17A in Pneumonic Plague Can Be Compensated by Effective Vaccines and Immunization Strategies in Mice. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/39772023 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39242587
GET https://conductscience.org/api/papers/v1/39242587/references?page=2